Bronchoconstriction

Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management

Retrieved on: 
Tuesday, June 6, 2023
Software, Pharmaceutical, Data Management, IOT (Internet of Things), Apps, Applications, Technology, Medical Devices, Health Technology, Health Insurance, Biotechnology, Wearables, Mobile Technology, Practice Management, Health, Hypersensitivity, Anti-inflammatory, Salbutamol, Angioedema, Rash, Pain, Contraindication, Prednisone, Adrenal insufficiency, Digital health, Patient, Risk, Common, SVP, Arrhythmia, Hyperthyroidism, Wheeze, Physician, Urinary tract infection, Innovation, ICS, Measles, Hypertension, Vomiting, Back pain, System, Anaphylaxis, Trauma, Death, Moyamoya disease, Sinusitis, Allergy, Fungus, Fever, Eye, Hypokalemia, Record, Parasitism, Chickenpox, Medicine, LABA, Hives, Tuberculosis, Immune system, Milk, Heart rate, Bronchoconstriction, Blood pressure, Infection, Teva Pharmaceuticals, Gastroenteritis, Partnership, Diabetes, Tricyclic, Simplex, EMR, Fatality, Respiratory disease, Inc., Itch, Lactose, Bronchospasm, Immunosuppression, Fluticasone/salmeterol, Pharmaceutical industry, Generic drug, Vaccine, Medical device, Asthma

The goal of Phil and Teva Pharmaceuticals’ partnership is to help enable patients to receive and refill their Digihaler medication quickly, easily and affordably.

Key Points: 
  • The goal of Phil and Teva Pharmaceuticals’ partnership is to help enable patients to receive and refill their Digihaler medication quickly, easily and affordably.
  • Using the PhilRx Patient Access Platform, patients can fill their prescription, review prescription records and obtain assistance navigating insurance benefits.
  • The PhilRx Patient Access Platform provides end-to-end visibility into the entire prescription life cycle, starting when the physician writes the prescription.
  • Physicians can select the PhilRx Patient Access Platform directly from an electronic medical record (EMR) to submit a prescription for a Digihaler product.

Royalty Pharma Reports First Quarter 2023 Results

Retrieved on: 
Tuesday, May 9, 2023
Asthma, Share repurchase, BioCryst Pharmaceuticals, Cohort, DPP, GAAP, Letermovir, Acquisition, Patient, Risk, Cystic fibrosis, Ageing, Ionis Pharmaceuticals, Psychiatry, Vertex, Cardiovascular disease, Aplastic anemia, Gilead, Bronchoconstriction, Growth, FDA, Calcitonin, Net, Pressure, Migraine, Psychosis, Schizophrenia, HER2, Cabozantinib, Leuprorelin, Psoriasis, Cytokinetics, Astellas Pharma, Progression-free survival, RCC, LVEF, Calendar, Exelixis, COVID, AstraZeneca, Sale, EBITDA, HCM, PureTech Health, Breast cancer, Generic drug, Bank, Video game, Pharmaceutical industry, Music, Bookkeeping, Ionis, Natalizumab, Sacituzumab govitecan, Ibrutinib, Salbutamol/budesonide, Elexacaftor/tezacaftor/ivacaftor, KarXT, Adjustment, Pfizer

As such, Royalty Pharma did not receive royalty receipts on Prevymis net sales in the first quarter of 2023 related to the fourth quarter of 2022.

Key Points: 
  • As such, Royalty Pharma did not receive royalty receipts on Prevymis net sales in the first quarter of 2023 related to the fourth quarter of 2022.
  • Drivers of royalty receipts in the first quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
  • Royalty Pharma acquired a royalty interest in Trelegy in July 2022 and began receiving royalty receipts in the third quarter of 2022.
  • Royalty Pharma will also receive 25% of Ionis’ mid-teens to low-20% royalty on net sales of pelacarsen, resulting in a mid-single digit royalty to Royalty Pharma.

Calyptus Pharmaceuticals Announces Approval of Arformoterol Tartrate Inhalation Solution, EQ 0.015 mg Base/2 ml

Retrieved on: 
Wednesday, August 24, 2022
Respiratory disease, Partnership, Chinese Pharmaceutical Association, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Arformoterol, Maintenance, Chronic obstructive pulmonary disease, Food, Bronchoconstriction, ANDA, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., FDA, COPD, Abbreviated New Drug Application, Anders (singer), Patient, Pharmaceutical industry, IQVIA

PRINCETON, N.J., Aug. 24, 2022 /PRNewswire/ --Calyptus Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration ("FDA") granted approval to an Abbreviated New Drug Application (ANDA) for a generic version of Brovana (Arformoterol Tartrate inhalation solution, EQ 0.015 mg Base/2 ml) to Calyptus' partner - VistaPharm, Inc., ("VistaPharm" - a Pharmaceutical Associates, Inc company).

Key Points: 
  • PRINCETON, N.J., Aug. 24, 2022 /PRNewswire/ --Calyptus Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration ("FDA") granted approval to an Abbreviated New Drug Application (ANDA) for a generic version of Brovana (Arformoterol Tartrate inhalation solution, EQ 0.015 mg Base/2 ml) to Calyptus' partner - VistaPharm, Inc., ("VistaPharm" - a Pharmaceutical Associates, Inc company).
  • Arformoterol Tartrate inhalation solution, EQ 0.015 mg Base/2 mlis indicated for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
  • The successful development, and approval of a generic formulation of Arformoterol Tartrate inhalation solution is a testimony to these efforts".
  • According to IQVIA, a leading healthcare data and analytics provider, U.S. annual sales for Arformoterol Tartrate inhalation solution, EQ 0.015 mg Base/2 mlfor the 12 months ended June 2022 were approximately $104 million.

US FDA accepts New Drug Application filed by Avillion for AstraZeneca's PT027 for the as-needed treatment or prevention of symptoms in asthma patients

Retrieved on: 
Tuesday, May 31, 2022
Inflammation, Risk, Budesonide, Medicine, Kidney, Food, US Foods, Cataract, International Conference on Nuclear Disarmament, Oslo, 2008, Asthma, International, Global Initiative for Asthma, Salbutamol, New Drug Application, Patient, File, Health, Treatment, American Thoracic Society, The New England Journal of Medicine, Pneumonia, SABA, Global Initiative, Thakeham, FDA, Bronchoconstriction, Partnership, ICS, Time, ATS, Conference, Safety, Wheeze, NDA, Drug development, Breathe Me, Depressive anxiety, OCS, MD, Cardiovascular disease, AstraZeneca, Pharmaceutical industry

The proposed indication is for the as-needed treatment or prevention of bronchoconstriction and for the prevention of exacerbations in patients with asthma 4 years of age and older.

Key Points: 
  • The proposed indication is for the as-needed treatment or prevention of bronchoconstriction and for the prevention of exacerbations in patients with asthma 4 years of age and older.
  • Under the terms of the agreement, Avillion funded, sponsored, and executed a multicentre, global clinical trial programme for PT027 comprising four studies involving more than 4,000 patients.
  • Following the successful approval of PT027, AstraZeneca has the option, upon certain financial payments, to commercialise the medicine in the US.
  • The NDA submission is based on data from studies conducted by AstraZeneca and Avillion to assess the safety and efficacy of PT027.

US FDA accepts New Drug Application filed by Avillion for AstraZeneca's PT027 for the as-needed treatment or prevention of symptoms in asthma patients

Retrieved on: 
Tuesday, May 31, 2022
Inflammation, Risk, Budesonide, Medicine, Kidney, Food, US Foods, Cataract, International Conference on Nuclear Disarmament, Oslo, 2008, Asthma, International, Global Initiative for Asthma, Salbutamol, New Drug Application, Patient, File, Health, Treatment, American Thoracic Society, The New England Journal of Medicine, Pneumonia, SABA, Global Initiative, Thakeham, FDA, Bronchoconstriction, Partnership, ICS, Time, ATS, Conference, Safety, Wheeze, NDA, Drug development, Breathe Me, Depressive anxiety, OCS, MD, Cardiovascular disease, AstraZeneca, Pharmaceutical industry

The proposed indication is for the as-needed treatment or prevention of bronchoconstriction and for the prevention of exacerbations in patients with asthma 4 years of age and older.

Key Points: 
  • The proposed indication is for the as-needed treatment or prevention of bronchoconstriction and for the prevention of exacerbations in patients with asthma 4 years of age and older.
  • Under the terms of the agreement, Avillion funded, sponsored, and executed a multicentre, global clinical trial programme for PT027 comprising four studies involving more than 4,000 patients.
  • Following the successful approval of PT027, AstraZeneca has the option, upon certain financial payments, to commercialise the medicine in the US.
  • The NDA submission is based on data from studies conducted by AstraZeneca and Avillion to assess the safety and efficacy of PT027.

Insights on the Asthma and COPD Drugs Global Market to 2030 - Key Players Include Novartis, Organon and Sanofi - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 3, 2022
Health, Pharmaceutical, Degenerative disease, Pain, Asthma, Pain scale, Respiratory disease, Prevalence, Leukotriene, Medication, COPD, Patient, Bronchus, Hospital, R, Combination, Wheeze, Air pollution, CAGR, Bronchoconstriction, Anticholinergic, Chronic obstructive pulmonary disease, Growth, Awareness, Pharmaceutical industry

The asthma and COPD drugs market was valued at $32988.7 million in 2020 and is projected to reach $52049.54 million by 2030, registering a CAGR of 4.64%% from 2021 to 2030.

Key Points: 
  • The asthma and COPD drugs market was valued at $32988.7 million in 2020 and is projected to reach $52049.54 million by 2030, registering a CAGR of 4.64%% from 2021 to 2030.
  • The increase in prevalence of asthma globally drives the growth of asthma and COPD drugs market.
  • In addition, increase in awareness about the respiratory diseases in people propels the growth of asthma and COPD drugs market.
  • Furthermore, initiatives taken by respective governments to treat and improve the lifestyle of asthma & COPD patients boosts market growth.

Kither Biotech announces publication of new data in Science Translational Medicine

Retrieved on: 
Thursday, March 31, 2022
Company, CFTR, Cell, Idiopathic pulmonary fibrosis, CF, Epithelium, SCI, Camp, Science Translational Medicine, Respiratory disease, Cystic fibrosis transmembrane conductance regulator, CEO, Cystic fibrosis, University of Turin, Pulmonology, MP, Bronchoconstriction, Degenerative disease, Inflammation, Signal transduction, DOI, COPD, Asthma, PKA, University, Patient, Disease, Pharmaceutical industry

Vincent Metzler, CEO at Kither Biotech, commented: The publication of these data in a prominent peer-reviewed journal represents an important step as we advance the development of KIT2014 for the treatment of cystic fibrosis as an add-on therapy to CFTR modulators.

Key Points: 
  • Vincent Metzler, CEO at Kither Biotech, commented: The publication of these data in a prominent peer-reviewed journal represents an important step as we advance the development of KIT2014 for the treatment of cystic fibrosis as an add-on therapy to CFTR modulators.
  • Kither Biotech is a biopharma company founded by Prof. Alessandra Ghigo, Prof. Emilio Hirsch, Prof. Alberto Bardelli and Marco Kevin Malisani.
  • Kither Biotech is a spin-off from the University of Turin and actively collaborates with the Molecular Biotechnology Center (University of Turin) and other research centres in the world.
  • In CF patients, treatment with KIT2014 is believed to restore the function of CFTR mutants by potentiating the effects of CFTR modulators (Ghigo et al., Science Translational Medicine, in press).

Kither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer

Retrieved on: 
Wednesday, March 16, 2022
PI3K, Commercial Operating System (COS), Novara, Degenerative disease, Idiopathic pulmonary fibrosis, University, Patient, University of Turin, Director, CFO, CFTR, Camp, Entrepreneurship, PKA, Pulmonology, Wilson Therapeutics, Cystic fibrosis, Ersel Hickey, Epithelium, Cell, Bronchoconstriction, Board, Science Translational Medicine, Company, Marketing, Inflammation, CEO, Jazz Pharmaceuticals, CF, Board of directors, Management, Financial services, Pharmaceutical industry, Growth, Gentium

Kither Biotech Raises 18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer

Key Points: 
  • Kither Biotech Raises 18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer
    International syndicate of new investors including Claris Ventures, 2 Invest, 3B Future Health Fund and Alef 6, with continued support from existing investors
    Turin, Italy, 16 March 2022 Kither Biotech (Kither or the Company), a biopharmaceutical company developing novel therapies for rare respiratory diseases, today announces that it has raised 18.5 million in a Series B financing round and has appointed current Board Member Dr. Vincent Metzler as Chief Executive Officer.
  • Kither also announces today the appointment of Dr. Vincent Metzler as Chief Executive Officer, while current CEO Marco Kevin Malisani transitions to the role of Chief Financial Officer and remains a member of the Board of Directors.
  • Dr. Vincent Metzler, CEO at Kither Biotech, commented: Kither is committed to developing transformative therapies for patients living with rare pulmonary diseases.
  • Heikki Lanckriet, newly appointed Non-executive Director at Kither Biotech said: I am excited to join the Kither Biotech board of directors at such an exciting phase.

Global Asthma Pipeline Market Research Report 2022: Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Health, Cardiology, People, Maintenance, Atmosphere, Republic, Therapy, National Medical Products Administration, Pharmacokinetics, No, AstraZeneca, NDA, Aluminium, Histamine, NMPA, Salbutamol, Budesonide, Discovery, House dust mite, DP2, II, Patent, Chronic obstructive pulmonary disease, Allergic rhinitis, Safety, Swelling, Company, Marketing, ILC2, Type 2, FP, Ileum, Intellectual property, Bronchoconstriction, Patient, Good, Eos, IP, Amgen, Clinical trial, Type, News, Mastocytosis, Omalizumab, AMG, Shijiazhuang Pharma Group, Income, Basophil, Inflammation, PGD2, III, Mergers and acquisitions, Antigen, Phleum, T helper cell, Technology, Veillonella parvula, Eosinophil, Allergen, COPD, Leukotriene, Anaphylaxis, 104, Pharmaceutical industry, Vaccine, Dactylis, Asthma

The publisher's, "Asthma - Pipeline Insight, 2022," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Asthma pipeline landscape.

Key Points: 
  • The publisher's, "Asthma - Pipeline Insight, 2022," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Asthma pipeline landscape.
  • It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Asthma R&D.
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Asthma therapeutics?

Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5032 as a Potential Treatment for Asthma

Retrieved on: 
Wednesday, February 9, 2022
NASDAQ, Obesity, Pain, GLOBE, Maintenance, Human, Growth, U.S. Securities and Exchange Commission, Allergy, AUD, Death, Disorder, Sheep, Time, Inflammatory bowel disease, Allergen, Research, Company, Cancer, Marketing, Ascaris, Asthma, Degenerative disease, Annual report, World, Inflammation, Sale, Infection, Opioid use disorder, Patient, Bruise, Security (finance), Antigen, Steroid, Bronchoconstriction, Drug development, Addiction, Diabetes, Drinking, Gambling, World Health Organization, Nature, Adenosine, Communication, Pharmaceutical industry, Vaccine, Nasdaq

CHARLOTTESVILLE, Va., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company), today announced positive in vivo data for PNV-5032, as a potential treatment for asthma.

Key Points: 
  • CHARLOTTESVILLE, Va., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company), today announced positive in vivo data for PNV-5032, as a potential treatment for asthma.
  • PNV-5032 demonstrated a significant inhibition of pulmonary flow resistance, which is a measure of asthmatic response, in an in vivo model.
  • After a washout/recovery period of a few weeks, PNV-5032 was nebulized and administered prophylactically to the sheep.
  • AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity.